Emergency department visits by adults for psychiatric medication adverse events

JAMA Psychiatry

Volumn 71, Issue 9, 2014, Pages 1006-1014

  Hampton, Lee M ^a   Daubresse, Matthew ^b,c   Chang, Hsien Yen ^b,c   Alexander, G Caleb ^b,c,d   Budnitz, Daniel S ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CENTRAL STIMULANT AGENT; CITALOPRAM; CLONAZEPAM; HALOPERIDOL; LITHIUM; LITHIUM SALT; LONG ACTING DRUG; LORAZEPAM; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PRESCRIPTION DRUG; QUETIAPINE; RISPERIDONE; SEDATIVE AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; ZOLPIDEM TARTRATE; HYPNOTIC SEDATIVE AGENT; LITHIUM DERIVATIVE; PSYCHOTROPIC AGENT;

ABNORMAL BEHAVIOR; ADULT; ADVERSE DRUG REACTION; AGED; AMBULATORY CARE; ARTICLE; BREATHING DISORDER; CARDIOVASCULAR DISEASE; CONSCIOUSNESS DISORDER; DESCRIPTIVE RESEARCH; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SURVEILLANCE PROGRAM; DYSTONIA; EMERGENCY CARE; EMERGENCY PATIENT; EMERGENCY WARD; EXTRAPYRAMIDAL SYMPTOM; FALLING; FEMALE; GASTROINTESTINAL SYMPTOM; HEAD INJURY; HEART PALPITATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; MIDDLE AGED; MOOD DISORDER; MOTOR DYSFUNCTION; MUSCLE DISEASE; OUTPATIENT CARE; PAIN; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; SENSORY DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SPASTICITY; TRISMUS; UNITED STATES; UNSPECIFIED SIDE EFFECT; URTICARIA; VERTIGO; YOUNG ADULT; AGE; EMERGENCY HEALTH SERVICE; EPIDEMIOLOGY; MENTAL DISORDERS; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ADULT; AGE FACTORS; AGED; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITALIZATION; HUMANS; HYPNOTICS AND SEDATIVES; LITHIUM COMPOUNDS; MALE; MENTAL DISORDERS; MIDDLE AGED; PSYCHOTROPIC DRUGS; SEX FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84907016697     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2014.436     Document Type: Article

References (44)

1. Substance Abuse and Mental Health Services Administration. Results From the 2011 National Survey on Drug Use and Health: Mental Health Findings. Rockville,MD: Substance Abuse and Mental Health Services Administration; 2012. NSDUH series H-45. HHS publication (SMA) 12-4725.
2. Leucht S, Hierl S, KisslingW, DoldM, Davis JM. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-Analyses. Br J Psychiatry. 2012;200(2):97-106.
3. Wilens TE, Spencer TJ. Understanding attention-deficit/hyperactivity disorder from childhood to adulthood. Postgrad Med. 2010;122 (5):97-109.
4. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am FamPhysician. 2010;81(5):617-622.
5. Glass J, Lanctǒt KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-Analysis of risks and benefits. BMJ. 2005;331(7526):1169. doi:http://dx.doi.org/10.1136/bmj.38623.768588.47.
6. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008;149(10):734-750.
7. American Psychiatric Association. Practice Guideline for the Treatment of PatientsWith Major Depressive Disorder, Third Edition. 2010. http://psychiatryonline.org/content.aspx?bookid=28& sectionid=1667485. Accessed July 25, 2013.
8. Hoge EA, Ivkovic A, Fricchione GL. Generalized anxiety disorder: diagnosis and treatment. BMJ. 2012;345:e7500. doi:10.1136/bmj.e7500.
9. Buysse DJ. Insomnia. JAMA. 2013;309(7): 706-716.
10. Bourgeois FT, ShannonMW, Valim C, Mandl KD. Adverse drug events in the outpatient setting: an 11-year national analysis. Pharmacoepidemiol Drug Saf. 2010;19(9):901-910.
11. Budnitz DS, Pollock DA,Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296 (15):1858-1866.
12. JhungMA, Budnitz DS, Mendelsohn AB, Weidenbach KN, Nelson TD, Pollock DA. Evaluation and overview of the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project (NEISS-CADES). Med Care. 2007;45(10)(suppl 2):S96-S102.
13. National Center for Health Statistics, Centers for Disease Control and Prevention. Ambulatory health care data. 2013. http://www.cdc.gov/nchs/ahcd/ahcd-questionnaires.htm. Accessed May 31, 2013.
14. National Center for Health Statistics, Centers for Disease Control and Prevention. Bridged-race population estimates data files and documentation. http://www.cdc.gov/nchs/nvss/bridged-race/data-documentation.htm#vintage2011. Accessed May 31, 2013.
15. National Center for Health Statistics, Centers for Disease Control and Prevention. Ambulatory Care Drug Database System. 2013. http://www.cdc.gov/nchs/ahcd/ahcd-database.htm. Accessed May 31, 2013.
16. Truven Health Analytics. Micromedex 2.0. 2013. http://www.micromedexsolutions.com/micromedex2/librarian/. Accessed June 3, 2013.
17. Food and Drug Administration. Drugs@FDA. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed June 3, 2013.
18. Burgyone K, Aduri K, Ananth J, Parameswaran S. The use of antiparkinsonian agents in the management of drug-induced extrapyramidal symptoms. Curr Pharm Des. 2004;10(18):2239-2248.
19. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365 (21):2002-2012.
20. Kish L. Survey Sampling. New York, NY: Wiley Interscience; 1995.
21. Huybrechts KF, Gerhard T, Crystal S, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ. 2012; 344:e977. doi:10.1136/bmj.e977.
22. Nasrallah HA, White T, Nasrallah AT. Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective data.AmJ Geriatr Psychiatry. 2004;12(4):437-439.
23. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011;20 (2):177-184.
24. American Board of Internal Medicine Foundation. APA releases list of common uses of psychiatric medications to question. September 20, 2013. http://www.choosingwisely.org/apa-releases-list-of-common-uses-of-psychiatric-medications-to-question/. Accessed September 20, 2013.
25. Christian R, Saavedra L, Gaynes BN, et al. Future Research Needs for First- and Second-Generation Antipsychotics for Children and Young Adults. Rockville,MD: Agency for Healthcare Research and Quality; 2012.
26. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. The DAWN Report: Emergency Department Visits for Adverse Reactions Involving the Insomnia Medication Zolpidem. Rockville, MD: Center for Behavioral Health Statistics and Quality; 2013.
27. Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Zolpidem use and hip fractures in older people. J AmGeriatr Soc. 2001;49(12):1685-1690.
28. Kolla BP, Lovely JK, Mansukhani MP, Morgenthaler TI. Zolpidem is independently associated with increased risk of inpatient falls. J HospMed. 2013;8(1):1-6.
29. Food and Drug Administration. FDA Drug Safety Communication: risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). 2013. http://www.fda.gov/drugs/drugsafety/ucm334033.htm. Accessed May 31, 2013.
30. MoloneyME, Konrad TR, Zimmer CR. The medicalization of sleeplessness: a public health concern. Am J Public Health. 2011;101(8):1429-1433.
31. National Center for Health Statistics, Centers for Disease Control and Prevention. Health, United States, 2012: With Special Feature on Emergency Care. Hyattsville, MD: National Center for Health Statistics; 2013.
32. Ward BW, Schiller JS. Prevalence of multiple chronic conditions among US adults: estimates from the National Health Interview Survey, 2010. Prev Chronic Dis. 2013;10:65. doi:10.5888/pcd10.120203.
33. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657-659.
34. Centers for Disease Control and Prevention (CDC). Emergency department visits involving nonmedical use of selected prescription drugs: United States, 2004-2008. MMWR Morb Mortal Wkly Rep. 2010;59(23):705-709.
35. OlfsonM, Blanco C,Wang S, Greenhill LL. Trends in office-based treatment of adults with stimulants in the United States. J Clin Psychiatry. 2013;74(1):43-50.
36. OlfsonM, Blanco C, Liu SM,Wang S, Correll CU. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012;69(12): 1247-1256.
37. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J AmColl Cardiol. 2003;41(1):56-61.
38. Higashi A, Zhu S, Stafford RS, Alexander GC. National trends in ambulatory asthma treatment, 1997-2009. J Gen Intern Med. 2011;26(12):1465-1470.
39. Bulloch AG, Bresee LC, Beck CA, Patten SB. Substantial changes in prescription recommendations for bipolar disorder in Canada: 2002-2010. Can J Psychiatry. 2012;57(4):263-268.
40. Dusetzina SB, Busch AB, Conti RM, Donohue JM, Alexander GC, Huskamp HA. Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory. Pharmacoepidemiol Drug Saf. 2012;21 (12):1251-1260.
41. Briesacher BA, Tjia J, Field T, Peterson D, Gurwitz JH. Antipsychotic use among nursing home residents. JAMA. 2013;309(5):440-442.
42. Kupfer DJ, Kuhl EA, Regier DA. DSM-5: the future arrived. JAMA. 2013;309(16):1691-1692.
43. Batstra L, Frances A. Holding the line against diagnostic inflation in psychiatry. Psychother Psychosom. 2012;81(1):5-10.
44. Hansen HB, Donaldson Z, Link BG, et al. Independent review of social and population variation in mental health could improve diagnosis in DSM revisions. Health Aff (Millwood). 2013;32(5): 984-993.